Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
| ▸ | PREP | P48147 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7005690 | 1.00 | HPGD (0.49) | HPGDGAAHSD17B10EPHX1PREP | |
| SCHEMBL1202111 | 1.00 | HPGD (0.49) | HPGDGAAHSD17B10EPHX1PREP | |
| SCHEMBL357043 | 0.95 | HSD17B10 (0.52) | HPGDHSD17B10EPHX1SMN1; SMN2NPC1 | |
| SCHEMBL178721 | 0.95 | HSD17B10 (0.52) | HPGDHSD17B10EPHX1SMN1; SMN2NPC1 | |
| SCHEMBL357042 | 0.95 | HSD17B10 (0.52) | HPGDHSD17B10EPHX1SMN1; SMN2NPC1 | |
| SCHEMBL31539240 | 0.88 | HPGD (0.48) | HPGDHSD17B10EPHX1PREPSMN1; SMN2 | |
| SCHEMBL27618621 | 0.88 | PREP (0.42) | HPGDGAAHSD17B10EPHX1PREP | |
| SCHEMBL4175218 | 0.87 | CHRM2 (0.44) | HPGDHSD17B10EPHX1PREPSMN1; SMN2 | |
| SCHEMBL489128 | 0.87 | CHRM2 (0.44) | HPGDHSD17B10EPHX1PREPSMN1; SMN2 | |
| SCHEMBL489126 | 0.87 | CHRM2 (0.44) | HPGDHSD17B10EPHX1PREPSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250206724-A1 | SUBSTITUTED 3-AMINO INDAZOLE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2025-06-26 | — | — | US | disclosed |
| EP-4499612-A1 | SUBSTITUTED 3-AMINO INDAZOLE DERIVATIVES AS KINASE INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2025-02-05 | — | — | EP | disclosed |
| CN-118974020-A | Substituted 3-aminoindazole derivatives as kinase inhibitors | 内尔维亚诺医疗科学公司 | 2024-11-15 | — | — | CN | disclosed |
| WO-2023186773-A1 | SUBSTITUTED 3-AMINO INDAZOLE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2023-10-05 | — | — | WO | disclosed |
| US-11766436-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2023-09-26 | — | — | US | disclosed |
| EP-4198024-A1 | PYRAZOLE MAGL INHIBITORS | H. Lundbeck A/S (DK) | 2023-06-21 | — | — | EP | disclosed |
| US-20210309638-A1 | 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2021-10-07 | — | — | US | disclosed |
| US-11053218-B2 | 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | NOVARTIS AG (CH) | 2021-07-06 | — | — | US | disclosed |
| US-20200231569-A1 | 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2020-07-23 | — | — | US | disclosed |
| WO-2020028115-A1 | 5-METHYL-4-FLUORO-THIAZOL-2-YL COMPOUNDS | ELI LILLY AND COMPANY (US) | 2020-02-06 | — | — | WO | disclosed |
| US-8987250-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-20140343042-A1 | NICOTINE RECEPTOR TARGETED COMPOUNDS AND COMPOSITIONS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2014-11-20 | — | — | US | disclosed |
| US-20130281433-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2013-10-24 | — | — | US | disclosed |
| US-8461328-B2 | Tricyclic heterocyclic compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-8461328-B2 | Tricyclic heterocyclic compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2011-08-18 | — | — | US | disclosed |
| CN-1863797-A | Cyclic amine BACE-1 inhibitors having a benzamide substituent | PHARMACOPEIA DRUG DISCOVERY (US) | 2006-11-15 | — | — | CN | disclosed |
| EP-1138679-B1 | HYDRONAPHTHO 2,3-c]FURAN DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF | SAGAMI CHEM RES (JP) | 2003-03-19 | — | — | EP | disclosed |
| US-6392059-B1 | THERAPY FOR ALZHEIMER'S DISEASE | SAGAMI CHEMICAL REASEARCH CENTER (JP) | 2002-05-21 | — | — | US | disclosed |
| EP-1138679-A1 | HYDRONAPHTHO 2,3-c]FURAN DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 2001-10-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250206724-A1 | SUBSTITUTED 3-AMINO INDAZOLE DERIVATIVES AS KINASE INHIBITORS | CDK1, CDK11A, CDK3 | HPGD 2141/4885GAA 3479/4885HSD17B10 3713/4885 |
| US-20130281433-A1 | THERAPEUTIC COMPOUNDS | NQO1, HAVCR2, CCR5 | HPGD 656/4885GAA 42/4885HSD17B10 1005/4885 |
| US-20210309638-A1 | 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | XDH, H1-0, RXFP1 | HPGD 888/4885GAA 1642/4885HSD17B10 3610/4885 |
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | CCNY, CCNA1, CCNA2 | HPGD 223/4885GAA 2545/4885HSD17B10 863/4885 |
| US-20140343042-A1 | NICOTINE RECEPTOR TARGETED COMPOUNDS AND COMPOSITIONS | CHRNA7, CHRNA5, CHRNA4 | HPGD 2162/4885GAA 1933/4885HSD17B10 1854/4885 |
| US-20200231569-A1 | 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | XDH, H1-0, RXFP1 | HPGD 888/4885GAA 1642/4885HSD17B10 3610/4885 |
| US-11766436-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | HPGD 2130/4885GAA 2321/4885HSD17B10 3826/4885 |
| US-11053218-B2 | 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | XDH, H1-0, RXFP1 | HPGD 888/4885GAA 1642/4885HSD17B10 3610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.